Metabolomics in exploratory toxicology: Consequences of treatment with the candidate chemopreventive agent pentamethylchromanol (PMCol)
Jonathan McDunn, PhD., Associate Director, Diagnostics Research and Development at Metabolomic Inc. and Adjunct Associate Professor of Biomedical Engineering, UNC-Chapel Hill
Sponsored by the Center for Environmental Health and Susceptibility